Do you initiate management of new onset diabetes in a patient on immunotherapy or refer immediately to endocrinology given the risk of rapid worsening?

Topics: Gynecologic Cancers • Medical Oncology • Immune-related adverse events • Rheumatology • Endocrinology • Gynecologic Oncology • Multispecialty Spotlight

Answer from: Medical Oncologist at Community Practice

New onset hyperglycemia during ICPi therapy warrants careful review of potential risk factors for type 2 diabetes mellitus (T2DM) and close monitoring of symptoms and lab results to distinguish from the rare and typically more threatening checkpoint inhibitor-associated diabetes mellitus (CIADM). Ne...

Comments

Medical Oncologist at Stephen B. Strum, MD PC
Dr. @Kathryn Bollin is certainly a wonderful asset...

Related Questions